<p>Orville Kolterman, MD has been the Chief Medical Officer at Pendulum since its launch. He is also an Adjunct Professor of Medicine at the University of California, San Diego. Orville has held a successful and distinguished 40 year medical career. During his 20 year tenure at Amylin, Orville served as the Chief Medical Officer, creating two of the first GLP-1l drugs, SYMLIN and BYETTA. Before Amylin, Orville was the Program Director of the General Clinical Research Center and Medical Director of the Diabetes Center at the University of California Medical Center.</p>
<p>Following graduation from the University of Kansas with a B.A. degree, Orville received a medical degree from Stanford University. He then completed his medical internship and residency at the University of Chicago prior to returning to Stanford for specialty training in Endocrinology and Metabolism.</p>
